z-logo
Premium
Expression of Concern: Tumour necrosis factor‐alpha‐induced protein 8 ( TNFAIP8 ) expression associated with cell survival and death in cancer cell lines infected with canine distemper virus
Author(s) -
Garcia J. A.,
Ferreira H. L.,
Vieira F. V.,
Gameiro R.,
Andrade A. L.,
Eugênio F. R.,
Flores E. F.,
Cardoso T. C.
Publication year - 2017
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12168
Subject(s) - oncolytic virus , canine distemper , apoptosis , programmed cell death , cytopathic effect , biology , cell culture , necrosis , virus , tumor necrosis factor alpha , virology , cell , cancer research , cancer cell , cancer , immunology , biochemistry , genetics
Oncolytic virotherapy is a novel strategy for treatment of cancer in humans and companion animals as well. Canine distemper virus ( CDV ), a paramyxovirus, has proven to be oncolytic through induction of apoptosis in canine‐derived tumour cells, yet the mechanism behind this inhibitory action is poorly understood. In this study, three human mammary tumour cell lines and one canine‐derived adenofibrosarcoma cell line were tested regarding to their susceptibility to CDV infection, cell proliferation, apoptosis, mitochondrial membrane potential and expression of tumour necrosis factor‐alpha‐induced protein 8 ( TNFAIP8 ). CDV replication‐induced cytopathic effect, decrease of cell proliferation rates, and >45% of infected cells were considered death and/or under late apoptosis/necrosis. TNFAIP8 and CDVM gene expression were positively correlated in all cell lines. In addition, mitochondrial membrane depolarization was associated with increase in virus titres ( p  < 0.005). Thus, these results strongly suggest that both human and canine mammary tumour cells are potential candidates for studies concerning CDV ‐induced cancer therapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here